<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230920059483N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-10</date_registration>
      <primary_sponsor>Combined Military Hospital Kharian, Pakistan</primary_sponsor>
      <public_title>Addition of neostigmine and atropine to standard post-dural puncture headache</public_title>
      <acronym></acronym>
      <scientific_title>Comparison between neostigmine and atropine added to standard post-dural puncture headache regimen versus standard regimen alone</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72737</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Double blind interventional randomized controlled trial.
This randomized controlled trial was carried out at Anesthesia department of Combined Military Hospital, Kharian
The patients were divided into the modified treatment group (Group M) (n=65) and the standard treatment group (Group S) (n=65) after randomization. One was given the standard regimen and the other received the modified regimen with atropine added. The method of randomization was simple non-probability consecutive sampling via lottery method. The lottery envelopes were placed in the pre-anesthesia clinic and patients presenting for treatment of PDPH were asked to pick one at random and segregated into one of the two groups. The randomization was done in sealed envelopes with the resident consultant on duty containing pre-prepared treatment vials as unmarked syringes to be given in both groups according to the treatment guide, Blinding description: This was a double-blind study and once the patients were divided into the two groups, both the drug administering anesthetist and the anesthetist recording the results were unaware of the study protocol or the randomization group details. The lottery envelopes were placed in the pre-anesthesia clinic and patients presenting for treatment of PDPH were asked to pick one at random and segregated into one of the two groups. The randomization was done in sealed envelopes with the resident consultant on duty containing pre-prepared treatment vials as unmarked syringes to be given in both groups according to the treatment guide. Both the patient as well as the resident giving the treatment was unaware of the drugs being given as well as the study protocol. Proforma for analysis was also marked with nondescript group to blind the assessor of the outcome of each group of study.</study_design>
      <phase>2</phase>
      <hc_freetext>Post dural puncture headache.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group M (Modified regimen group) Patients in the modified regimen received the same protocol and drugs of the standard regimen as well as IV neostigmine 20 mcg/kg and atropine 10 mcg/kg in 20 ml in the same 8 hourly intervals till the time pain threshold on the visual analog scale was &lt;3. Patients with VAS &lt;3 before 72 hours were still given 20 ml of 0.9% normal saline to maintain blinding. Intervention 2: Intervention group: Group S (Standard regimen group) Patients in the standard regimen received the institute followed conservative management of IV Paracetamol 15mg/kg, IV Ibuprofen 5 mg/kg, IV Ondansetron 4 mg, IV Omeprazole 40 mg, Ringer lactate at 1.5 ml/kg/hr and caffeine 135 mg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be shared after the manuscript approval by the concerned publishing journal. Request to be forwarded to the main focal person given in details by email and after permission would be shared by email to the requesting person/organization.

When:
After approval of manuscript for publication and would be available with the focal person and organization indefinitely

To whom:
For research and academic institutions after permission from the focal person.

Conditions:
For research and academic purposes only
Focal person given in details and email address provided to be used for all queries

Where to obtain:
From the focal person via email after formal request and approval from the institute. Process would be done by the focal person.

How to obtain:
A formal email requesting the data required with official name and designation of the person requiring. Would be given after focal person receives confirmation from own institute to share the data. Approximate processing time 7-10 days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Qaim Ali Bhatti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>CMH hospital , kharian cantt</address>
        <city>Kharian</city>
        <country1>Pakistan</country1>
        <zip>50090</zip>
        <telephone>+92 331 6333113</telephone>
        <email>qaimalibhatty@gmail.com</email>
        <affiliation>Combined Military Hospital Kharian</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Qaim Ali Bhatti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>CMH hospital , kharian cantt</address>
        <city>Kharian</city>
        <country1>Pakistan</country1>
        <zip>50090</zip>
        <telephone>+92 331 6333113</telephone>
        <email>qaimalibhatty@gmail.com</email>
        <affiliation>Combined military hospital kharian</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Included all patients with post-dural puncture headache diagnosed according to the International Headache Society Criteria, presenting to the anesthesia clinic 48-72 hours after caesarian delivery.</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients unwilling for IV or oral therapy
Refusal to be included in the study
Patients with allergy to either atropine, neostigmine, paracetamol and/or ibuprofen
Patients with known history of migraine, cluster headache, patients on anti-depressants
Patients with any neurological disease and patients with major respiratory and cardiac disease.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G44</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other headache syndromes</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group M (Modified regimen group) Patients in the modified regimen received the same protocol and drugs of the standard regimen as well as IV neostigmine 20 mcg/kg and atropine 10 mcg/kg in 20 ml in the same 8 hourly intervals till the time pain threshold on the visual analog scale was &lt;3. Patients with VAS &lt;3 before 72 hours were still given 20 ml of 0.9% normal saline to maintain blinding.</i_keyword>
      <i_keyword>Intervention group: Group S (Standard regimen group) Patients in the standard regimen received the institute followed conservative management of IV Paracetamol 15mg/kg, IV Ibuprofen 5 mg/kg, IV Ondansetron 4 mg, IV Omeprazole 40 mg, Ringer lactate at 1.5 ml/kg/hr and caffeine 135 mg.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain on Visual Analog Scale. Timepoint: 6,12,24,48,72 hours after intervention. Method of measurement: Standard Visual Analog Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Nausea. Timepoint: Within 72 hours after intervention. Method of measurement: Patient history and observation in the wards.</sec_outcome>
      <sec_outcome>Neck stiffness. Timepoint: Within 72 hours after intervention. Method of measurement: Physical examination.</sec_outcome>
      <sec_outcome>Need for blood patch. Timepoint: Within 72 hours of intervention. Method of measurement: Non-responsive to standard IV treatment after 24 hours.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Combined Military Hospital Kharian, Pakistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-25</approval_date>
        <contact_name>Ethical review board CMH Kharian, Pakistan</contact_name>
        <contact_address>Main GT Road Kharian Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
